Radiopharm Theranostics Limited
RADXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 4, 2026 | H.C. Wainwright | $6.00(+34%) | $4.49 | TheFly | |
| Dec 17, 2025 | Maxim Group | Michael Okunewitch | $15.00(+163%) | $5.70 | TheFly |
| Nov 26, 2025 | B.Riley Financial | Yuan Zhi | $13.00(+174%) | $4.75 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| B. Riley Securities | maintain | Buy | Dec 16, 2025 |
| B. Riley Securities | maintain | Buy | Nov 26, 2025 |
Earnings History
Next report: Feb 26, 2027 · EPS est. $-1.05| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 28, 2026 | $-1.20 | $-1.67 | $699.3K | $845.2K |
| Feb 27, 2026 | $-2.25 | $-1.51 | $987.4K | $664.5K |
| Aug 29, 2025 | $-1.78 | $-1.58 | $1.5M | $652.9K |
| Feb 28, 2025 | $-1.91 | $-1.49 | $863.6K | $648.8K |
| Feb 29, 2024 | $-14.10 | — | — | — |
| Feb 28, 2023 | $-8.71 | — | $197.7K | — |
| Aug 30, 2022 | $-1.47 | — | — | — |
| Feb 27, 2022 | $-31.83 | — | — | — |
News
Single, multicenter Phase 3 imaging trial of approximately 280 patients with brain metastases designed to demonstrate sensitivity and specificity above prespecified performance thresholds
Phase 3 imaging trial of RAD101 in recurrent brain metastases from solid tumors expected to initiate in 1Q27 following successful end-of-phase 2 meeting with U.S. Food and Drug Administration
Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the targeting potential of RAD301 and continuation of its clinical development SYDNEY, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceutical…
Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company's joint venture with MD Anderson Cancer Center Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company's joint venture with MD Anderson Cancer Center
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ: RADX - Get Free Report)'s share price traded down 8.4% during mid-day trading on Thursday. The stock traded as low as $2.23 and last traded at $2.29. 88,911 shares changed hands during trading, a decline of 41% from the average daily volume of 151,981 shares. The stock had
Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated clinical proof-of-concept with positive safety and biodistribution SYDNEY, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for ar…